Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2017 08:00 ET | Source: AveXis

AveXis to Report First Quarter 2017 Financial and Operating Results

CHICAGO, May 04, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
April 25, 2017 10:33 ET | Source: AveXis

AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

– 10 of 12 patients on proposed therapeutic dose sat unassisted; patient videos demonstrate motor milestone achievement not seen in natural history of disease – – 86% of patients without feeding...
April 18, 2017 08:00 ET | Source: AveXis

AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology

– Includes Results from Phase 1 Trial of AVXS-101 in SMA Type 1 – – Conference call and webcast Tuesday, April 25 at 4:30 p.m. EDT – CHICAGO, April 18, 2017 (GLOBE NEWSWIRE) -- AveXis,...
March 16, 2017 16:05 ET | Source: AveXis

AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results

– No new treatment-related safety or tolerability findings – – No new events reported and 15 of 15 patients event-free at 13.6 months of age; majority of patients receiving proposed therapeutic dose...
March 09, 2017 08:00 ET | Source: AveXis

AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017

-- Conference call and webcast on March 16 at 4:30 p.m. EDT -- CHICAGO, March 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments...
March 02, 2017 16:05 ET | Source: AveXis

AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting

CHICAGO, March 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
February 15, 2017 08:00 ET | Source: AveXis

AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer

CHICAGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
February 06, 2017 08:00 ET | Source: AveXis

AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients

CHICAGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
January 31, 2017 08:00 ET | Source: AveXis

AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1

CHICAGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
January 03, 2017 08:00 ET | Source: AveXis

AveXis to Present at the 35th Annual J.P. Morgan Healthcare Conference

CHICAGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...